Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

PHASE4CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hypertension
Interventions
DRUG

Valsartan + HCTZ

At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.

DRUG

Valsartan

At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.

DRUG

HCTZ

At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.

Trial Locations (20)

Unknown

Investigative site, Birmingham

Investigative site, Phoenix

Investigative Site, Escondido

Investigative site, Fresno

Investigative site, Huntington Park

Investigative Sites, Pismo Beach

Investigative site, Miami

Investigative site, Ormond Beach

Investigative site, Conyers

Investigative Site, Lexington

Investigative site, Portland

Investigative site, Las Vegas

Investigative site, Buffalo

Investigative site, Shelby

Investigative site, Carlisle

Investigative site, Oklahoma City

Investigative site, Erie

Investigative Site, Greer

Investigative Site, Taylors

Investigative site, St. George

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY